Why the study?
Are apixaban, dabigatran, and rivaroxaban cost-effective alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation?
Population
Patients with nonvalvular atrial fibrillation and an increased risk of stroke
Comparison
Apixaban 5 mg, dabigatran 150 mg, and… vs Warfarin
Design
Other
Authors
Loading...
May inform NOAC selection in nonvalvular AF; leaves open effects of US pricing and rivaroxaban event rates.
Are apixaban, dabigatran, and rivaroxaban cost-effective alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation?
Novel oral anticoagulants (apixaban, dabigatran, and rivaroxaban) are cost-effective alternatives to warfarin for stroke prevention in atrial fibrillation within the US healthcare context.
Harrington et al. (2013) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: